T cells are central to the body's defense ... anti-tumor immunity is an emerging area in cancer therapy, systemically inhibiting Tregs can cause severe autoimmune reactions. This challenge has ...
“Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has transformed the treatment of refractory B ... including reduction of immunosuppressive regulatory T cells (Tregs), and reprogramming ...
UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which could be worth up to $2 ...